ISPOR’s Top 10 HEOR Trends for 2024-2025

By Staff Writer

January 12, 2024

Introduction:

The International Society for Health Economics and Outcomes Research (ISPOR) recently released its biennial report detailing the top 10 Health Economics and Outcomes Research (HEOR) trends for 2024-2025. This report, the fifth of its kind, offers a compelling glimpse into the future of healthcare. Providing key trends such as Real-World Evidence (RWE), drug pricing, and Artificial Intelligence (AI) taking centre stage.

The Dominance of Real-World Evidence:

RWE has consistently featured in ISPOR’s reports, therefore appearing as the top trend in the three most recent publications. It is increasingly being used to supplement Randomised Controlled Trials (RCTs) in healthcare decision-making, highlighting its growing significance in the industry.

The Recurring Theme of Drug Pricing:

Drug pricing remains a critical concern, featuring as the second trend in the report. However, the introduction of the Inflation Reduction Act (IRA) in the United States, which allows Medicare to negotiate drug prices, could potentially impact global drug development and innovation.

The Rise of Artificial Intelligence:

AI, the third trend, is becoming an integral part of our daily lives and the healthcare sector. From chatbots to machine learning, AI is being utilised in various ways to provide valuable insights in HEOR.

Balancing Innovation and Affordability:

Furthermore, the fourth trend focuses on fostering innovation while ensuring affordable pricing. This balance is vital for the development of new technologies in the healthcare sector.

In conclusion, the ISPOR HEOR trends report presents a comprehensive overview of the top trends shaping the future of healthcare. As pressures on healthcare systems worldwide continue to increase, these trends provide invaluable insights for stakeholders to inform and improve healthcare decisions.

Reference url

Recent Posts

newborn screening sickle cell
      

Advancing Newborn Screening for Sickle Cell Disease in Africa

🌍 How can newborn screening for Sickle Cell Disease transform health outcomes in Africa?

Discover the pivotal role of the Consortium on Newborn Screening in Africa (CONSA) in combating SCD—a severe health issue affecting hundreds of thousands of newborns each year. Early diagnosis and intervention can significantly enhance the quality of life and reduce mortality rates. Join us in exploring the global implications of this vital initiative and how it can inform healthcare systems worldwide.

#SyenzaNews #GlobalHealth #HealthcareInnovation #SickleCellDisease #HealthForAll

GLP-1 thyroid cancer risk
    

Diabetes Drugs Safe from Thyroid Cancer Risk, Study Finds

🔍 Are GLP-1 analogues safe for thyroid health?

A recent study has found no significant association between popular diabetes medications and an increased risk of thyroid cancer. This reassuring result is essential for patients and healthcare providers, clearing the air on concerns surrounding the long-term safety of these treatments. Read more about the implications for thyroid health awareness and the ongoing need for research.

#SyenzaNews #healthcare #clinicaltrials #innovation #healthcarepolicy

WINREVAIR Pulmonary Hypertension
       

Abu Dhabi Introduces WINREVAIR: A Major Breakthrough in Pulmonary Arterial Hypertension Treatment

🚀 Ready to learn about an innovative treatment for Pulmonary Arterial Hypertension in Abu Dhabi?

The introduction of WINREVAIR by the Department of Health marks a significant leap in improving patient outcomes. This innovative medication promises to enhance life expectancy and quality of life for those affected by this challenging condition.

Discover how this therapy is set to improve the landscape of PAH treatment in the region!

#SyenzaNews #HealthcareInnovation #pharmaceuticals #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.